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Abstract
Background: The PD-1/PD-L1 axis plays a paramount role in the immune escape of tumor cells by negative
regulation of T-cell functions. The aim of the present study was to characterize the PD-L1 expression pattern
and its clinical implication in soft-tissue sarcomas (STS).
Methods: We analyzed PD-L1 expression in 82 STS patients with 5 subtypes: rhabdomyosarcoma, synovial sarcoma,
Ewing sarcoma, epithelioid sarcoma, and mesenchymal chondrosarcoma.
Results: The median age at diagnosis was 26 (range: 1–78) and the male to female ratio was 1.6. The majority
(80 %) of patients showed locoregional disease rather than metastatic disease at diagnosis. Thirty-five cases (43 %)
showed PD-L1 expression and the proportion of PD-L1 expression was significantly different according to histologic
subtypes (P = 0.004); highest in epithelioid sarcoma (100 %, 7/7), followed by synovial sarcoma (53 %, 10/19),
rhabdomyosarcoma (38 %, 12/32), and Ewing sarcoma (33 %, 6/18), while it was not expressed in mesenchymal
chondrosarcoma (0 %, 0/6). STS patients with PD-L1 expression had worse overall survival compared with those
without PD-L1 expression (5-year survival rate: 48 % vs. 68 %, P = 0.015). The Cox proportional hazard model
adjusted for histologic subtype, initial metastasis, and PD-L1 expression showed that PD-L1 expression was
significantly associated with shorter overall survival (P = 0.037, HR 2.57, 95 % CI 1.060–6.231).
Conclusion: We have confirmed PD-L1 expression in various STS of young population and demonstrated its
independent negative prognostic role, thereby suggesting the PD-1/PD-L1 axis as a potential therapeutic target
for the treatment of young STS patients.
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Background
Sarcomas are a rare and highly heterogeneous group of
neoplasms originating from the bone and soft tissue,
which account for <1 % of all human malignancies [1, 2].
With strikingly variable genetic aberrations, various
sarcomas have abnormal fusion proteins arising from
translocations. In spite of the multimodality treatments
with surgery, radiotherapy, and combination chemotherapy,
more than 40 % of cases ultimately experience tumor
recurrence, which results in an overall survival (OS)
of <12 months [3]. There are still only a few treatment
options left when conventional treatment fails; thereby,
novel anti-cancer therapeutics are desperately needed to
treat these devastating diseases.
It is well known that the prognosis of a malignant
tumor is closely related to host immune responses.
During the immune response, the priming and activation
of T-cells are critical processes in the induction of adap-
tive immunity, and the ultimate amplitude of the immune
response is regulated by a balance between co-stimulatory
and inhibitory signals. In this T-cell-mediated process,
cytotoxic T-lymphocyte antigen 4 (CTLA-4) provides in-
hibitory signals in the priming phase of the T-cell response
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within the lymph node. The programmed death 1 (PD-1)
receptor is one of the key inhibitory signals that is induced
during the chronic antigen exposure in peripheral tumor
microenvironments. The interaction between PD-L1
in tumor cells and PD-1 in T-lymphocytes negatively
regulates the effector function of tumor-specific T-
lymphocytes and allows tumor cells to evade the host
immune system. Recent studies have indicated that high
expression of PD-L1 is associated with poor prognosis
in non-small cell lung cancer (NSCLC), ovarian can-
cer, and kidney cancer [4–7]. Furthermore, because
anti-PD-1 antibodies were approved in melanoma and
lung cancer with robust efficacy and safety profiles,
much attention has paid to the PD-L1 expression in
various solid malignancies. However, the presence of
PD-L1 and its clinical implications in sarcoma have
not been widely investigated to date.
In this study, we investigated PD-L1 expression in soft
tissue sarcoma and evaluated its clinical relevance ac-
cording to different subtypes of sarcoma. We thereafter
analyzed the prognostic potential of PD-L1 to provide a
practical guide as a diagnostic and therapeutic strategy.
Methods
Patients and tissue samples
This study was conducted in a retrospective cohort of
patients who were pathologically diagnosed with CD99
positive sarcomas such as rhabdomyosarcoma, synovial
sarcoma, Ewing sarcoma, epithelioid sarcoma, and mesen-
chymal chondrosarcoma, between 1994 and 2013 at
Yonsei Cancer Center. A total of 82 formalin-fixed,
paraffin-embedded tissue blocks were available for
examination of PD-L1 expression. All hematoxylin and
eosin (H&E) slides were independently reviewed by two
experienced pathologists (E.K.K. and S.H.K).
The clinicopathologic variables such as sex, age, max-
imal tumor size, tumor histology and grade, tumor loca-
tion, tumor stage, initial presentation of disease, and the
status of the resection margin were reviewed retrospect-
ively based on electronic medical records. Tumors were
graded according to the French Federation Nationale
des Centre de Lutte Contre le Cancer (FNCLCC) criteria
[8]. Staging was determined using the 7th edition of the
American Joint Committee on Cancer guideline of
tumor, node, and metastasis (TNM) classification. The
study was approved by the institutional review board of
Severance Hospital, Seoul, Korea.
Tissue microarray (TMA) construction
Simple, inexpensive, and precise paraffin TMAs were
constructed with a conventional microcompound table
and a drill grinder. The original H&E slides were
reviewed by two pathologists (E.K.K and S.H.K). One or
two different tumor areas per case were selected for
tissue microarray construction. Core tissue biopsies
(3 mm in diameter) were taken from the individual paraf-
fin blocks (donor blocks) and arranged in recipient paraf-
fin blocks (tissue array blocks) using a trephine apparatus.
All TMA blocks were confirmed by H&E staining.
Immunohistochemical staining and assessment
Immunohistochemistry (IHC) staining of PD-L1 was
performed on the TMA blocks using a mouse monoclo-
nal antibody for PD-L1 (clone 130021, R&D Systems,
Minneapolis, MN). Four-micrometer-thick sections were
prepared and stained using a Ventana automatic immu-
nostainer (Ventana, Benchmark, Tucson, AZ) [9]. After
deparaffinization, heat-induced antigen retrieval was
performed using pH 6.0 citrate buffer (CC1 protocol,
Ventana, Tucson, AZ), and reactivity was detected using
the Cell Mark detection kit (catalog no. 315-M-94). The
sections were incubated with the primary antibody for
32 min at room temperature (dilution 1:100). The slides
were counterstained with hematoxylin. Positivity for PD-
L1 was evaluated and determined independently by two
experienced pathologists (E.K.K. and S.H.K). In the case
of discrepancy, a consensus was made through an in-
depth discussion on multi-head microscopic observa-
tions. The intensity and percentage of PD-L1 positive
tumor cells were counted manually in at least 100 viable
tumor cells from 4 representative fields in each case. Be-
cause there was no consensus on the scoring system for
PD-L1 expression, especially in sarcoma, we modified
the previous protocol [10] and describe PD-L1 expres-
sion as much detail as possible by a semi-quantitative
manner using the intensity multiplied by the proportion.
The staining intensity was graded as negative (0), weak
to moderate (1), or strong (2), and the proportion was
categorized by the percentage of positive cells as 0, no
positive tumor cells; 1+, less than 10 %; 2+, 10–50 %;
and 3+, >50 %. Based on the multiplication score, a
score of 0 or 1 was considered as negative PD-L1 ex-
pression, whereas scores greater than 2 were considered
positive PD-L1 expression.
Statistical methods
The Statistical Package for the Social Sciences (SPSS)
version 18.0 (IBM, Chicago, IL) was used for statistical
analyses. The correlations between PD-L1 expression
and clinicopathologic variables were analyzed using the
independent sample t-test for the continuous variables
and the chi-square test for the discrete variables. For
survival analysis, recurrence-free survival (RFS) was de-
fined as the time interval between surgery and tumor re-
currence or last follow-up. OS was defined as the time
interval between the diagnosis of metastatic/recurrent
disease and death or last follow-up. Survival analysis was
performed using the Kaplan-Meier method with the
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log-rank test. Multivariate analyses for OS were performed
with Cox’s regression. The accepted level of statistical
significance was P < 0.05.
Results
Patient characteristics
The baseline clinicopathologic characteristics of the pa-
tients are summarized in Table 1. The male-to-female ratio
was 1.6:1, and the median age at the time of diagnosis was
26 years (range 1–78). The median tumor size was 5 cm,
and two-thirds of cases showed low- or intermediate-grade
tumors. Approximately half of the cases were rhabdomyo-
sarcoma (n = 32, 39 %), followed by synovial sarcoma
(n = 19, 23 %), Ewing sarcoma (n = 19, 22 %), epithelioid
sarcoma (n = 7, 9 %), and mesenchymal chondrosarcoma
(n = 6, 7 %). One third of the tumors were located in the
extremities (n = 27, 33 %). Most patients had no distant
metastasis at the time of diagnosis (82 %) and underwent
surgical resection (93 %). Adjuvant chemotherapy was
administered to 47 patients (57 %), and 37 of these pa-
tients (79 %) also received adjuvant radiotherapy.
PD-L1 expression status and clinicopathologic features
Among the 82 sarcoma patients, PD-L1 was expressed
in 35 cases (43 %). Representative images of PD-L1-
positive and -negative staining for each histologic type
are shown in Fig. 1. In the positive cases, PD-L1 was
positive in the cytoplasmic membrane of the tumor cells
and intratumoral endothelial cells. PD-L1 expression
was significantly different according to the histologic
subtype of sarcoma (P = 0.004). The proportion of PD-
L1-expressing tumors was highest in epithelioid sarcoma
(100 %, 7/7), followed by synovial sarcoma (53 %, 10/19),
rhabdomyosarcoma (38 %, 12/32), and Ewing sarcoma
(33 %, 6/18), whereas it was not expressed in mesenchymal
chondrosarcoma (0 %, 0/6). Patients with PD-L1 expres-
sion had a more negative resection margin than the PD-
L1-negative group (86 % vs. 62 %, P = 0.017). There was no
Table 1 Baseline characteristics
Variables PD-L1 expression P
valueN (%) - +
Sex Male 50 (61 %) 31 (66 %) 19 (54 %) 0.284
Female 32 (39 %) 16 (34 %) 16 (46 %)
Age (year, median, range) 26 (1–78) 26.3 ± 19.7 30.6 ± 20.0 0.773
Tumor size (cm, median, range) 5.0 (1.5–12.0) 5.0 ± 1.8 5.3 ± 1.7 0.711
Histologic type Rhabdomyosarcoma 32 (39 %) 20 (43 %) 12 (34 %) 0.004
Synovial sarcoma 19 (23 %) 9 (19 %) 10 (29 %)
Ewing sarcoma 18 (22 %) 12 (26 %) 6 (17 %)
Epithelioid sarcoma 7 (9 %) 0 (0 %) 7 (20 %)
Mesenchymal chondronsarcoma 6 (7 %) 6 (13 %) 0 (0 %)
Tumor location Trunk 13 (16 %) 9 (19 %) 4 (11 %) 0.073
Abdomen/pelvis 20 (24 %) 14 (30 %) 6 (17 %)
Head/Neck 22 (27 %) 14 (30 %) 8 (23 %)
Extremities 27 (33 %) 10 (21 %) 17 (49 %)
FNCLCC Grade 1 17 (21 %) 11 (23 %) 6 (17 %) 0.242
2 34 (41 %) 19 (40 %) 15 (43 %)
3 31 (38 %) 17 (36 %) 14 (40 %)
Initial distant metastasis No 67 (82 %) 38 (81 %) 29 (83 %) 0.816
Yes 15 (18 %) 9 (19 %) 6 (17 %)
Surgery No 6 (7 %) 2 (4 %) 4 (11 %) 0.217
Yes 76 (93 %) 45 (96 %) 31 (89 %)
Resection margin Negative 59 (72 %) 29 (62 %) 30 (86 %) 0.017
Positive 23 (28 %) 18 (38 %) 5 (14 %)
Chemotherapy No 35 (43 %) 21 (45 %) 14 (40 %) 0.672
Yes 47 (57 %) 26 (55 %) 21 (60 %)
Radiotherapy No 45 (55 %) 26 (55 %) 19 (54 %) 0.926
Yes 37 (45 %) 21 (45 %) 16 (46 %)
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significant difference in PD-L1 expression regarding age,
sex, tumor size, location, histologic grade, surgical resec-
tion, and adjuvant treatment.
Survival outcome according to PD-L1 expression
After a median follow-up duration of 33.8 months, 27
patients (33 %) had died at the time of survival analysis.
The 5-year OS for all patients was 58.8 % and the 5-year
OS rates of the subgroups were as follows: 64 % for
rhabdomyosarcoma, 77 % for synovial sarcoma, 39 % for
Ewing sarcoma, 18 % for epithelioid sarcoma, and 100 %
for chondrosarcoma. There was a trend toward a worse
RFS for the positive PD-L1 expression group compared
to the negative group (Fig. 2a). Expression of PD-L1 in
the tumor tissue significantly predicted shortened OS
(5-year OS rate, 48 % vs. 68 %; hazard ratio [HR] = 2.545;
95 % confidence interval [CI] = 1.16–5.56; P = 0.015,
Fig. 2b). Because the study cohort includes patients with
initial distant metastasis and this could influence the sur-
vival outcome, we also analyzed the RFS and OS after ex-
cluding patients with metastatic disease. The trend for
RFS and OS were almost comparable whether we exclude
Fig. 1 Immunohistochemical staining of PD-L1 expression. Representative images of PD-L1-positive and -negative sarcoma samples
Fig. 2 Survival analyses according to PD-L1 expression. a Kaplan-Meier survival curves for recurrence-free survival (RFS). b Kaplan-Meier survival
curves for overall survival (OS)
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or not the metastatic patients (Additional file 1: Figure S1).
The clinicopathologic variables significantly correlated with
OS by univariate analysis were histologic subtype, initial
metastasis, and PD-L1 expression (Table 2). In the Cox
proportional hazard model adjusted for histologic subtype,
initial metastasis, and PD-L1 expression, PD-L1 expression
was significantly associated with shorter OS (P = 0.037,
HR = 2.57, 95 % CI = 1.06–6.23).
Discussion
In this study, we evaluated the clinical relevance of PD-
L1 expression in various sarcoma subtypes. PD-L1 was
differently expressed according to the histologic subtypes
of sarcoma and it was found to be an independent prog-
nostic factor for OS.
William Coley, a bone surgeon at New York Memorial
Hospital, depicted the spontaneous tumor regression of
sarcoma patients after severe bacterial infection more
than 100 years ago [10, 11]. Subsequently, there were
several reports related to the cure of metastatic sarcoma
with aggressive surgical resection, which suggested a po-
tential therapeutic role of immune surveillance [12].
Since then, the interest in immunotherapy for sarcoma
treatment has risen and fallen. Hypothetically, because
several types of sarcoma have a common and specific
chromosomal translocation, the resulting fusion proteins
may be potential tumor neoantigens that could be ap-
propriate targets for immunotherapy [13].
Based on this theoretical background, numerous clinical
trials were attempted in sarcoma patients with various im-
munomodulatory agents such as macrophage-colony
stimulating factor (GM-CSF), peptide vaccines, and anti-
CTLA-4 antibody [14–16]. Inhaled GM-CSF was intro-
duced for 43 patients with first isolated pulmonary recur-
rence of osteosarcoma [14]. Although this treatment
seemed feasible with low toxicity, no immunomodulatory
effect or improved outcome was observed. Another study
with the anti-CTLA-4 antibody ipilimumab for synovial
sarcoma was halted due to poor accrual and no clinical
response [16]. Besides these disappointing results in
previous clinical trials, there have been few studies explor-
ing potential therapeutic targets for immunotherapy in
sarcoma conducted to date.
Recently, with the impressive and outstanding success
of pembrolizumab and nivolumab in melanoma, NSCLC,
and other malignancies [17, 18], immune checkpoint in-
hibitors have come into the limelight for the treatment of
various solid tumors. Although numerous trials of PD-1/
PD-L1 inhibitors are ongoing for various solid tumors,
there has been minimal research to investigate the clinical
significance of the PD-1/PD-L1 axis in sarcoma. In the
present study, we revealed that 42.7 % of the sarcoma pa-
tients had positive expression of PD-L1, which varied ac-
cording to histologic subtypes. Epithelioid and synovial
sarcoma had higher positive expression rates (100 and
53 %), whereas mesenchymal chondrosarcoma cases re-
vealed no PD-L1 expression. This finding suggests that
PD-L1 expression is also heterogeneous according to dif-
ferent histologic subtypes of sarcoma, and that PD-L1
blockade could be a novel and promising therapeutic
strategy in this orphan tumor.
The PD-1/PD-L1 expression level has been reported
to be related to poor survival in other solid tumors. In a
previous report of renal cell carcinoma, PD-1 expression
in tumor-infiltrating lymphocytes was observed in half
of the cases and was associated with poor survival [7].
Moreover, PD-L1 expression was reported in half of the
gastric cancer and lung cancer cases and was an inde-
pendent negative prognostic factor for OS [19, 20]. In the
present study, in addition to determining the frequency of
PD-L1 expression according to histologic subtypes, we
were able to demonstrate the prognostic role of the intra-
tumoral PD-L1 expression in sarcoma. PD-L1 was signifi-
cantly associated with shorter 5-year OS regardless of sex,
Table 2 Univariate and multivariate analysis for overall survival
Variables Univariate Multivariate
5-years OS P-value HR (95 % CI) P-value
Sex (Male vs. Female) 63 % vs. 52 % 0.553
Age (≥20 vs. <20) 60 % vs. 57 % 0.871
Tumor size (≥5 cm vs. <5 cm) 53 % vs. 65 % 0.136
Histologic type (Epi. Sarcoma vs. Others) 18 % vs. 63 % 0.004 1.459 (0.414–5.137) 0.556
Tumor location (Axial vs. Extremity) 57 % vs. 63 % 0.423
Initial metastasis (Yes vs. No) 33 % vs. 65 % 0.034 2.335 (0.858–6.351) 0.097
Surgery (Yes vs. No) 62 % vs. 40 % 0.069
Margin status (Positive vs. Negative) 51 % vs. 62 % 0.819
Adjuvant therapy (Yes vs. No) 58 % vs. 65 % 0.921
PD-L1 expression (Yes vs. No) 48 % vs. 68 % 0.015 2.490 (1.032–6.007) 0.042
HR hazard ratio, CI confidence interval
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age, tumor size, histology, location, surgical outcome, and
adjuvant treatment, implying that PD-L1 is an independ-
ent negative prognostic factor in sarcoma.
Moreover, besides the prognostic value of PD-L1 ex-
pression in human cancers, it is becoming increasingly
recognized as an important biomarker for predicting the
treatment efficacy of PD-1/PD-L1 blockade. In the
KEYNOTE-012 phase IB trial (Clinical Trials.gov Identi-
fier; NCT01848834) [21], patients with advanced gastric
cancer were screened for PD-L1 expression (positivity
was defined as PD-L1 expression in ≥ 1 % of cells in
tumor nests or according to stromal staining using IHC
with the 22C3 PD-L1 antibody), and 41 % were PD-L1-
positive cases. After treatment with an anti-PD-1 anti-
body, pembrolizumab, a promising objective response
rate (22 %), 6-month progression free survival (26 %),
and 6-month OS (66 %) were observed. Furthermore,
Herbst et al. [22] reported the association of PD-L1 expres-
sion in tumor-infiltrating immune cells with the response
to an anti-PD-L1 monoclonal antibody, MPDL3280A, in
which 83 % of IHC 3+ NSCLC cases showed a response,
whereas the response rate was less than 20 % in IHC 0–1+
cases. In contrast to the above-stated findings, the survival
outcome for another anti-PD-1 antibody, nivolumab, was
not significantly different according to PD-L1 subgroup in
melanoma patients [23]. Taken together, the predictive
value of PD-L1 expression under treatment with PD-1/PD-
L1 immune checkpoint inhibitors has not yet been fully
established, and therefore further validation is strongly
warranted through further studies.
Unfortunately, the IHC criteria for PD-L1 expression
have not yet been standardized. Indeed, different defini-
tions of positive PD-L1 expression have been used in the
clinical trials conducted to date. In the CheckMate 017
study with NSCLC patients, OS and response rate were
significantly better with nivolumab than with docetaxel,
regardless of the PD-L1 expression level [17]. PD-L1 ex-
pression (of tumor cells only) was neither prognostic
nor predictive of nivolumab efficacy in the study. A
prospective study with pembrolizumab, KENOTE-010,
confirmed the clinical usefulness of the tumor proportion
score (PD-L1 expression in at least 1 % of tumor cells)
[24]. Considering that patients with a higher tumor pro-
portion score (≥50 %) had a significantly increased benefit
compared to those with a lower score (≥1 %), further stud-
ies are required to determine the appropriate cutoff value
of the proportion score. Furthermore, because previous
studies reported marked intra-patient discordance and
longitudinal heterogeneity of PD-L1 assays, rigorous
validation with clinical trials are still needed [25].
Comprehensive incorporation with tumor-infiltrating
cells [26], inflammatory gene signatures [27], or the
immune microenvironment [28] will be helpful to
improve patient identification. Currently, a blueprint
project to comprehensively compare various PD-L1 assay
are ongoing by FDA and ASCO (Sholl et al. Arch Pathol
Lab Med 2016), we can wait these results to answer this
important question.
The main limitations of our study include its patient
selection, small sample size, and imbalance of histologic
type. Because we initially intended to analyze the PD-L1
expression in CD99 positive tumors, this study mainly
enrolled pediatric STS, which could result in relatively
younger median age of patients and longer survival
outcome. Moreover, due to the small sample size and
imbalance of histologic type between PD-L1 positive
and negative groups, especially epithelioid sarcoma
and mesenchymal chondrosarcoma, there could be a
possibility of type I error. Therefore, our findings
should be validated in an independent STS cohort
and according to the response to PD-1/PD-L1 inhibi-
tors in future clinical trials.
Conclusion
In conclusion, we have revealed PD-L1 expression in
various STS of young population and demonstrated its
independent negative prognostic role, thereby suggesting
the PD-1/PD-L1 axis as a potential therapeutic target for
the treatment of young STS patients.
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Additional file 1: Figure S1. Survival analyses according to PD-L1
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